docetaxel
sanofi,aventis
[]
ph2 et-02: nal-iri + 5-fu vs docetaxel as 2l therapy in poorly differentiated extra-pulmonary nec 6-mo pfs 32.1% vs 14.8% primary end-point met in nal-iri + 5-fu arm docetaxel considered futile if nal-iri unavailable -&gt; folfiri preferred over taxane #asco22 
??Medical Oncologist, MSc, PhD. GI/neuroendocrine/GU tumors/breast cancer ??Hospital Universitario UFC-CE, Oncologia D’Or